\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Study of Neuron-Specific Enolase as Potential Biomarker for Assessing the Severity and Outcome in Patients with Cerebrovascular Accidents}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2014-01-15 (revised: 15 January 2014)} \def\TheID{\makeatother } \def\TheDate{2014-01-15} \title{Study of Neuron-Specific Enolase as Potential Biomarker for Assessing the Severity and Outcome in Patients with Cerebrovascular Accidents} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{sangita mahadeo patil} \author[2]{Dr. Padalkar Ramchandra K.} \author[3]{Dr. Bhagat onali S} \affil[1]{ MUHS university} \renewcommand\Authands{ and } \date{\small \em Received: 8 December 2013 Accepted: 5 January 2014 Published: 15 January 2014} \maketitle \begin{abstract} Background: Stroke is the third cause of death and foremost cause of disability worldwide. Cerebrovascular accident or stroke is an emergency condition which require immediate procedure by a neurologist. Determination of extent of brain damage at the onset of the seizure is an appropriate action to determine therapy and prognosis. Increased serum neuron specific enolase can be expected to differentiating stroke types at the onset of the seizure.Aim: The goal of present study was to measure diagnostic value of serum neuron specific enolase in various types of cerebrovascular accident as well as to evaluate the clinical performance of neuron specific enolase in early diagnosis of cerebrovascular accident. \end{abstract} \keywords{cerebrovascular accident, ischemic stroke, hemorrhagic stroke, neuron specific enolase, brain damage.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Conclusion:}]{Conclusion:}\par Present study shows that, assessment of serum neuron specific enolase level may be a useful Marker for severity in cerebrovascular accident like ischemic stroke and hemorrhagic stroke and it may be well correlated with neurological disability and short term functional outcomes. \section[{Introduction}]{Introduction}\par troke or cerebrovascular accident (CVA) is the third leading cause of death after cardiovascular disease and cancer \hyperref[b0]{(1)}. In fact it is a leading cause of morbidity and mortality in major industrial countries. Approximately 20 million people each year are suffer from stroke (2).\par India will face enormous socio-economic burden to meet the cosis of rehabilitation of stroke victims. Because the population, it is now surviving through peak years (age 55-65years) of occurrence of stroke \hyperref[b1]{(3)}.\par The two major mechanisms causing brain damage in stroke are ischemia and hemorrhage. The effects of ischemia are fairly rapid because the brain does not store glucose, the chief energy substrate and is incapable of anaerobic metabolism. Intracerebral hemorrhage originates from deep penetrating vessels and causes injury to brain tissue by disrupting connecting pathways and causing localized pressure injury. \hyperref[b2]{4} The diagnostic and management of CVA is limited by lack of rapid diagnostic assay for use in emergency setting. In recent years, neurobiochemical markers of brain damage have gained particular attention in the identification of stroke patients with an adverse neurological outcome. The serum Neuron -Specific Enolase (NSE) level is one of these markers which can provide early information about neuronal damage. 5\par Neuron -specific Enolase (NSE; EC 4.2.1.11) is an acidic soluble protein which functions as glycolytic isoenzyme. It is a 78 kD gamma homodimer and represents the dominant enolase isoenzyme which found in the cytoplasm of neurons and cells with neuroendocrine differentiation. 6 ischemia and traumatic head injury provides a reliable laboratory indicator of the degree of brain cell damage and may allow for early prediction of outcome. 7 An increased NSE concentration in blood has been reported in patients with small cell lung cancer, neuroblastoma and neurological disorders. 7, 8\par Thus, in view of above information and several risk of complication, it is worthwhile to study the various biomarkers in CVA. Very few studies have been reported from serum NSE testing and its application in Indian context. The initial aim of our study was to measure the serum NSE levels in various types of CVA within in 72 hours of admission. Furthermore, the remarkable intention of present research was to evaluate the clinical performance of NSE in early diagnosis of CVA and monitoring tool for early prediction of ischemic stroke. \section[{II.}]{II.} \section[{Material and Method}]{Material and Method}\par The present diagnostic case-control study was conducted at department of Biochemistry in PDVVPF's Medical College Ahmednagar with all participants providing informed consent and utmost care was taken during experimental procedure according to the declaration of Helsinki 1975. hours of admission to exclude patients with stroke mimic. Approximately 5 ml blood was collected by venipuncture from anticubital vein of the forearm of each subject in plain vaccutainer (yucca diagnostic) under aseptic conditions within 72 hrs after admission and centrifuged for serum collection. Serum was stored at 20 0 C until assay was run to evaluate. All samples were thawed and analyzed in a single series. \section[{III.}]{III.}\par Method 1) Determination of serum NSE: Serum NSE was measured with commercially available quantitative enzyme linked immune sorbent assay (ELISA) kit which based on biotin double antibody sandwich technology. Add serum containing NSE to well that is pre-coated with NSE monoclonal antibody and then incubate. After incubation, add NSE antibodies labeled with biotin to unite with streptavidin-HRP, which forms the immune complex. Remove unbound enzymes after incubation and washing, then add chromomegnic reagent A and B. colour change blue to yellow with effect of acid which positively correlated with concentration of human NSE. 9, 10\par Statistical analysis: The statistical analysis was carried out by using the SYSTAT software package for window version 12. The students "t" test was applied for the statistical analysis and the results were expressed in mean± Standard Deviation (mean ±SD).p values p<0.05 for NSE were considered to be statistically significant. The Receiver Operating Characteristic (ROC) curve analysis and the area under the curve were performed for determination of diagnostic performance of serum NSE in the all patients included in the study. The optimum cutoff values for determination of serum NSE were selected from ROC analysis. This optimum cutoff was used to dichotomously classify positive or negative serum NSE level, and used for calculating of diagnostic sensitivity and specificity.\par IV. \section[{Results}]{Results}\par Baseline demographic and clinical characterization of the patients and healthy controls groups are given in table-1 there were no significant differences between the groups in age, gender. \section[{Discussion}]{Discussion}\par Stroke causes a vast amount of death and disability throughout the world. It is important to have sufficiently sensitive marker for brain damage that can be determined in blood instead of cerebrospinal fluid because blood samples can be taken more frequently and more independent of raised intracranial pressure than cerebrospinal samples. 11 Evaluation of enzyme level in Cerebrospinal fluid or serum has evoked keen interest as a simple, economical, reliable and easily available method for the evaluation of severity, course and prognosis and to some extent in the differential diagnosis of various types of CVA.Ischemia causes a cascade of event that eventually leads to neuronal damage and cell death. 12 NSE is the predominant enolase found in neural tissue, and the structural characteristics of this enolase allow for greater stability in high chloride concentrations compared with enolase in other organ system. 7\par In the current study, Serum neuron specific enolase levels were increased significantly (p<0.05) in the ischemic stroke group and hemorrhagic stroke as compared to controls group. Our results are strongly supported to previous reports. 5,11,13, Increased NSE level in CVA may be due to cute CNS such as cerebral infarction, hypoxia, trauma and seizure the blood -brain barrier is altered and astroglial disintegration results in leakage of NSE into the serum and cerebrospinal fluid. \hyperref[b11]{13} Schaarschmidt H et. al. research where they have studied the NSE in relation to the severity CVA . They verified that, plasma NSE level is seen as a relevant parameter for assessing the prognosis of cerebral ischemia. Additionally it may prove to be a useful tool for monitoring space occupying brain infarctions and intracerebral hemorrhage and therefore may contribute to improved therapeutic management of severe cerebrovascular diseases. 11\par Numbers of researchers have focused on the study of NSE in various types of CVA. Aparna Pandey et al have showed that initial serum NSE level may be a useful marker for severity in acute ischemic stroke and it may be well correlated with neurological disability and short term functional outcomes. They also suggested that, serum NSE may be used as an indicator of outcome in cerebral infarction patients. \hyperref[b12]{14} Natheer H. Ravi and Karim M. Aantiyah have demonstrated that, salivary NSE alone or in combination with serum can be used as valuable diagnostic for measurement of neuronal damage in patients with stroke and stroke related diseases. According to them, in ischemic stroke, the integrity of blood-brain barrier is disrupted to various degrees in these patients and leakage of this enzyme outside the CNS can be seen in salivary secretion. \hyperref[b11]{13} Takaaki kirino et al have documented that, NSE as a reliable enzymatic indicator of axon injury, regeneration and in particular of target innervations and reinnervation. 6\par In cross-sectional comparative study, Diwi L Lukas et al have examined and compared serum NSE level in ischemic and hemorrhagic stroke patients according to lesion volume and also analyzed correlation between serum NSE level and lesion volume in CT scan as gold standard. According to them, serum NSE level in acute stroke patients (24-48 hours) after onset can be used to estimate the extent of brain damage (lesion volume) but it cannot be used to differentiate the type of stroke. \hyperref[b13]{15} In present study, furthermore diagnostic performance of Serum NSE for diagnosis of ischemic stroke and hemorrhagic stroke were analyzed. The optimum diagnostic cut off point maximizing the sensitivity and specificity was determined to be 40 ng/ml with a sensitivity of 87.10 \% and specificity 95\% the area under ROC curve for NSE was 0.84. Our results are completely conformity with Hill et al study. They found that in a single examination, NSE had sensitivity of 89\%. They also suggested that, in the future the examination of neurobiochemical marker panel like serum NSE, Myelin basic protein, Protein S-100 B etc can be used not only to differentiate the type of stroke but also to differentiate the subtype of acute stroke. \hyperref[b14]{16} In addition, Natheer H Rawi and Karim M Atiyah have accomplished the diagnostic performance of NSE in patients with ischemic stroke and stroke prone patients. According to their result, the area under the ROC curve for serum NSE was significantly higher (0.960) compared to salivary NSE (0.825). The optimum cut-off value for serum NSE showing the highest diagnostic accurancy (90\%) was ? 13.1?g/L. This cut-off threshold showed optimum specificity (100\%) and reasonable sensitivity (85\%). \section[{VI.}]{VI.} \section[{Conclusion}]{Conclusion}\par Our finding indicate that, serum NSE as brain biomarker in CVA had elevated compared to controls which provides insight into the pathophysiologic mechanism of brain injury. Serum NSE in CVA patients after onset (<72hours) may be used to estimate the extent of neuronal damage and can be reliable parameter for weigh up CVA.\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{21}\includegraphics[]{image-3.png} \caption{\label{fig_1}Figure- 2 Figure 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.85\textwidth}} Results: serum neuron specific enolase (p<0.05)\\ concentrations was significantly higher in cerebrovascular\\ accident than healthy controls. Sensitivity, specificity, positive\\ predictive value and negative predictive value of neuron\\ specific enolase for detection of cerebrovascular accident\\ were 87.10\%, 95.00\%, 92.74\% and 87.69\%. The area under\\ the receiver operating characteristic curve of neuron specific\\ enolase in cerebrovascular accident was 0.84.\end{longtable} \par {\small\itshape [Note: Aim: The goal of present study was to measure diagnostic value of serum neuron specific enolase in various types of cerebrovascular accident as well as to evaluate the clinical performance of neuron specific enolase in early diagnosis of cerebrovascular accident.Methods: A diagnostic case control study was conducted on 60 patients were admitted within 72 hours of onset of stroke in the department of neurology and department of medicine of PDVVPF's Medical College and hospital Ahmednagar and 60 healthy age and sex matched volunteers formed the control group. Serum neuron specific enolase level was estimated by commercially available quantitative enzyme linked immune sorbent assay (ELISA) kit which based on biotin double antibody sandwich technology.Statistical analysis used: The student t test was used to compared patients and control. Receiver operating characteristic curve for neuron specific enolase was established to determined cut-off point. The sensitivity and specificity of neuron specific enolase for detection of cerebrovascular accident were analyzed.]} \caption{\label{tab_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.4171560402684564\textwidth}P{0.009983221476510068\textwidth}P{0.011409395973154362\textwidth}P{0.057760067114093955\textwidth}P{0.28808724832214766\textwidth}P{0.06560402684563758\textwidth}} \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep CVA\\ \tabcellsep Variables\tabcellsep \tabcellsep Controls (n=60)\tabcellsep Ischemic stroke (n=32)\tabcellsep Hemorrhagic stroke (n= 28)\\ \multicolumn{2}{l}{Age in years}\tabcellsep \tabcellsep 40.1± 12.34\tabcellsep 41.3±14.06\tabcellsep 43.1± 13.01\\ \multicolumn{3}{l}{Gender (Men/Women)}\tabcellsep 28/30\tabcellsep 19/13\tabcellsep 11/27\\ Systolic (mmHg)\tabcellsep blood\tabcellsep pressure\tabcellsep 110 ± 15.03\tabcellsep 119.15± 30.11\tabcellsep 120.07 ± 35.16\\ \multicolumn{2}{l}{Diastolic blood (mmHg)}\tabcellsep Pressure\tabcellsep 75.62 ± 5.04\tabcellsep 81.42± 14.28\tabcellsep 79.53 ± 16.02\\ \multicolumn{2}{l}{Cigarette Smokers (n)}\tabcellsep \tabcellsep ------\tabcellsep 07\tabcellsep 15\\ \multicolumn{2}{l}{Tobacco Chewing(n)}\tabcellsep \tabcellsep ------\tabcellsep 26\tabcellsep 19\\ \multicolumn{2}{l}{Atrial fibrillation (n)}\tabcellsep \tabcellsep 07\tabcellsep 06\tabcellsep 04\\ DM (n)\tabcellsep \tabcellsep \tabcellsep 9\tabcellsep 12\tabcellsep 8\\ \multicolumn{2}{l}{Serum NSE ( ng/ml)}\tabcellsep \tabcellsep 14.55± 12.41\tabcellsep 43.63± 13.41*\tabcellsep 45.63± 15.89*\\ \multicolumn{5}{l}{Values were expressed in mean with Standard Deviation (mean±SD),}\tabcellsep \\ \multicolumn{4}{l}{*Statistically highly significant,(p<0.001)}\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{n =numbers}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{As shown in table-1, Serum neuron specific}\tabcellsep \multicolumn{2}{l}{table-2. Sensitivity, specificity, positive predictive value}\\ \multicolumn{4}{l}{enolase levels were increased significantly (p<0.05) in}\tabcellsep \multicolumn{2}{l}{and negative predictive value were 84.38\%, 95.00\%,}\\ \multicolumn{4}{l}{the ischemic stroke Group (43.63±13.41) and}\tabcellsep \multicolumn{2}{l}{90.00\% and 91.94\% respectively in Ischemic stroke.}\\ \multicolumn{4}{l}{hemorrhagic stroke (45.63±15.89) as compared to}\tabcellsep \multicolumn{2}{l}{Similarly, in hemorrhagic stroke, Sensitivity, specificity,}\\ \multicolumn{2}{l}{controls group (14.55±12.64).}\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{positive predictive value and negative predictive value}\\ \multicolumn{4}{l}{The performance of Serum NSE for diagnosis of}\tabcellsep \multicolumn{2}{l}{were 89.29\%, 95.00\%, 89.29\% and 95.00\%.}\\ \multicolumn{4}{l}{ischemic stroke and hemorrhagic stroke is presented in}\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_1}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.21610169491525422\textwidth}P{0.1248587570621469\textwidth}P{0.1248587570621469\textwidth}P{0.192090395480226\textwidth}P{0.192090395480226\textwidth}} Types of CVA\tabcellsep Sensitivity (\%)\tabcellsep Specificity (\%)\tabcellsep Positive Predictive Value (\%)\tabcellsep Negative Predictive Value (\%)\\ Ischemic Stroke\tabcellsep 84.38\tabcellsep 95.00\tabcellsep 90.00\tabcellsep 91.94\\ Hemorrhagic stroke\tabcellsep 89.29\tabcellsep 95.00\tabcellsep 89.29\tabcellsep 95.00\end{longtable} \par \caption{\label{tab_2}Table 2 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Fisher and Schaebitz ()]{b10}\label{b10} ‘An overview of acute stroke therapy. Past, present and future’. M Fisher , W Schaebitz . \textit{Arch Intern Med} 2000. 160 p. . \bibitem[Hill et al. ()]{b14}\label{b14} ‘Biochemical markers in acute ischemic stroke’. M D Hill , D Jackowski , N Bayer . \textit{Canadian Medical Association Journal} 2000. 162 (8) p. . \bibitem[Bharosay et al. ()]{b3}\label{b3} ‘Correlation of Brain biomarker neuron specific enolase (NSE) with degree of disability and neurological worsening in cerebrovascular stroke’. Anuradha Bharosay , Vikram Vivek , Meena Bharosay , Kiran Varma , Ajoy Saxena , Ravi Sodani , Saxena . \textit{Ind J Clin Biochem} 2012. 27 (2) p. . \bibitem[Pause and Risberg ()]{b8}\label{b8} ‘Establishment and Evalution of a radioimmunoassay for neuron -specific enolase’. E Pause , T Risberg . \textit{Tumor Biol} 1989. 10 p. . \bibitem[Pause and Nustad ()]{b7}\label{b7} ‘Immunoradiometric assay for ag and gg-Enolase (Neuron Specific Enolase), with use of Monoclonal antibodies and Magnetizable Polymer particles’. E Pause , K Nustad . \textit{Clin. Chem} 1989. 35 p. . \bibitem[Kirino et al. ()]{b4}\label{b4} \textit{Neuron-specific enolase as index of neuronal regeneration and reinnervation. The journal of neuroscience}, Takaaki Kirino , Milton W Brightman , Wolfgang H Oertel , Donald E Schmechel , Paul J Marangos . 1983. 3 p. . \bibitem[Schaarschmidt et al. ()]{b9}\label{b9} ‘Neuron-Specific enolase concentration in blood as a prognostic parameters in cerebrovascular diseases’. H Schaarschmidt , H W Prange , H Reiber . \textit{Stroke} 1994. 25 p. . \bibitem[Imad A J Thanoon et al. ()]{b0}\label{b0} ‘Oxidative stress and C-reactive protein in patients with cerebrovasacular Accident (The role of Ginkgo biloba extract)’. Imad A J Thanoon , A S Hilmy , Abdul Jabbar , A Dhia , Tana . \textit{SQU MED J} 2012. 12 (2) p. . \bibitem[Shah ()]{b2}\label{b2} \textit{Pathophysiology for education and research in neurological emergencies. 1-15}, Sid Shah , MD . 2012. \bibitem[Jaspreet Kaur et al. ()]{b1}\label{b1} ‘role of oxidative stress in pathphysiology of Transient Ischeic Attack and stroke Int’. Arova Jaspreet Kaur , Bhawna Singh , J Thakur , Gambhir . \textit{J Biol Med. RPS} 2011. 2011 (3) p. . \bibitem[Dwi et al. ()]{b13}\label{b13} ‘Role of serum neuron specific enolase (NSE) to differentiate ischemic stroke from hemorrhagic stroke and its correlation with brain damage volume’. Lily Dwi , Endang Lukas , Saiful Retnowati , Islam . \textit{Folia Medica Indonesiana} 2007. 43 (4) p. . \bibitem[Natheer et al. ()]{b11}\label{b11} ‘Salivary neuron specific enolase: an indicator for neuronal damage in patients with ischemic stroke and stroke-prone patients’. H Natheer , Al-Rawi , M Karim , Atiyah . \textit{Clin Chem Lab Med} 2009. 47 p. . \bibitem[Pandey et al. ()]{b12}\label{b12} ‘Serum neuron specific enolase as predictor of neurological disability and short term outcome in ischemic stroke’. Aparna Pandey , Amit Shirvastava , Kiran Saxena . \textit{Journal of Scientific and Innovative Research} 2013. 2 (2) p. . \bibitem[Bonner et al. ()]{b5}\label{b5} ‘Significance of neuron specific enolase levels before and during therapy of small cell lung cancer’. J A Bonner , J A Sloan , K M Rowland , G G Kleen , J W Kugler , J A Mailliard . \textit{Clin Cancer Res} 2000. 6 p. . \bibitem[Lima et al. ()]{b6}\label{b6} ‘Use of neuron -specific enolase for assessing the severity and outcome in patients with neurological disorders’. J E Lima , O M Takayanagui , Garcia Lv , J P Leite . \textit{Brazilian Journal of Medical and Biological Research} 2004. 37 p. . \end{bibitemlist} \end{document}